Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004916 · ClinicalTrials.gov registry record · Phase 1
Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004916: Completed Phase 1 study, sponsored by Northwestern University.
NCT00004916 is a Phase 1 study that has completed, run by Northwestern University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004916, a Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of ifosfamide, teniposide, and paclitaxel in treating patients who have relapsed non-Hodgkin's lymphoma.
Interventions
- DRUG paclitaxel
- DRUG ifosfamide
- PROCEDURE peripheral blood stem cell transplantation
- DRUG teniposide
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-02 |
| Est. Completion | 2002-10 |
| Phase | Phase 1 |
What the finished NCT00004916 record still lists
NCT00004916 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which paclitaxel is the first listed.
NCT00004916 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004916 about?
NCT00004916 is a clinical study titled "Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of ifosfamide, teniposide, and paclitaxel in treating patients who h...
What is the current status of trial NCT00004916?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-02. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00004916?
The interventions under investigation include: paclitaxel (DRUG), ifosfamide (DRUG), peripheral blood stem cell transplantation (PROCEDURE), teniposide (DRUG).
Who is sponsoring clinical trial NCT00004916?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia